All patients
age >= 60 yr autoimmune disease invasive ventilation no oxygen needed non invasive oxygen
corticosteroids in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results GLUCOCOVID, 2020 0.63 [0.25; 1.60]
Jamaati, 2021 1.19 [0.38; 3.72]
Metcovid, 2020 0.92 [0.67; 1.28]
REMAP-CAP, fixed 7-day course, 2020 1.03 [0.54; 1.98]
REMAP-CAP, shock-dependent course, 2020 1.10 [0.58; 2.10]
Tang X, 2020 0.98 [0.93; 1.02]
0.98 [0.93 ; 1.02 ] GLUCOCOVID, 2020, Jamaati, 2021, Metcovid, 2020, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Tang X, 2020 6 0% 1,069 moderate not evaluable death or transfer to ICUdetailed results GLUCOCOVID, 2020 0.68 [0.37; 1.25]
0.68 [0.37 ; 1.25 ] GLUCOCOVID, 2020 1 0% 63 NA not evaluable deathsdetailed results CAPE-COVID, 2020 0.45 [0.20; 1.02]
CODEX (Tomazini), 2020 0.97 [0.72; 1.31]
DEXA-COVID19, 2020 2.00 [0.21; 18.87]
Edalatifard, 2020 0.29 [0.15; 0.56]
GLUCOCOVID, 2020 0.63 [0.25; 1.60]
Jamaati, 2021 1.19 [0.38; 3.72]
Metcovid, 2020 0.92 [0.67; 1.28]
RECOVERY dexamethasone, 2020 0.83 [0.75; 0.92]
REMAP-CAP, fixed 7-day course, 2020 0.94 [0.61; 1.45]
REMAP-CAP, shock-dependent course, 2020 0.98 [0.63; 1.53]
Steroids-SARI, 2020 0.91 [0.29; 2.86]
Tang X, 2020 0.98 [0.93; 1.02]
0.87 [0.76 ; 0.99 ] CAPE-COVID, 2020, CODEX (Tomazini), 2020, DEXA-COVID19, 2020, Edalatifard, 2020, GLUCOCOVID, 2020, Jamaati, 2021, Metcovid, 2020, RECOVERY dexamethasone, 2020, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Steroids-SARI, 2020, Tang X, 2020 12 56% 8,091 moderate low deaths (time to event analysis only)detailed results Edalatifard, 2020 0.29 [0.15; 0.56]
REMAP-CAP, fixed 7-day course, 2020 0.94 [0.61; 1.45]
REMAP-CAP, shock-dependent course, 2020 0.98 [0.63; 1.53]
0.67 [0.35 ; 1.31 ] Edalatifard, 2020, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020 3 81% 560 serious not evaluable clinical deteriorationdetailed results CODEX (Tomazini), 2020 0.66 [0.43; 1.02]
Tang X, 2020 1.00 [0.13; 7.45]
0.67 [0.44 ; 1.03 ] CODEX (Tomazini), 2020, Tang X, 2020 2 0% 385 moderate not evaluable clinical improvementdetailed results Edalatifard, 2020 12.00 [2.39; 60.20]
REMAP-CAP, fixed 7-day course, 2020 1.43 [0.91; 2.26]
REMAP-CAP, shock-dependent course, 2020 1.22 [0.76; 1.95]
Tang X, 2020 1.04 [0.67; 1.62]
1.44 [0.89 ; 2.33 ] Edalatifard, 2020, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Tang X, 2020 4 65% 686 serious not evaluable clinical improvement (14-day)detailed results REMAP-CAP, fixed 7-day course, 2020 1.29 [0.82; 2.03]
REMAP-CAP, shock-dependent course, 2020 1.03 [0.65; 1.64]
Tang X, 2020 1.33 [0.57; 3.11]
1.18 [0.87 ; 1.59 ] REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Tang X, 2020 3 0% 584 serious not evaluable clinical improvement (time to event analysis only)detailed results Tang X, 2020 1.04 [0.67; 1.62]
1.04 [0.67 ; 1.62 ] Tang X, 2020 1 0% 86 NA not evaluable death or ventilationdetailed results CAPE-COVID, 2020 0.71 [0.37; 1.35]
RECOVERY dexamethasone, 2020 0.92 [0.84; 1.01]
REMAP-CAP, fixed 7-day course, 2020 2.74 [1.16; 6.46]
REMAP-CAP, shock-dependent course, 2020 1.24 [0.55; 2.78]
1.09 [0.71 ; 1.68 ] CAPE-COVID, 2020, RECOVERY dexamethasone, 2020, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020 4 59% 5,783 moderate not evaluable hospital dischargedetailed results CAPE-COVID, 2020 1.67 [0.87; 3.19]
RECOVERY dexamethasone, 2020 1.10 [1.03; 1.17]
1.19 [0.86 ; 1.64 ] CAPE-COVID, 2020, RECOVERY dexamethasone, 2020 2 37% 6,574 moderate not evaluable mechanical ventilationdetailed results CAPE-COVID, 2020 0.95 [0.44; 2.04]
Jamaati, 2021 1.38 [0.45; 4.20]
Metcovid, 2020 1.19 [0.56; 2.49]
RECOVERY dexamethasone, 2020 0.77 [0.62; 0.95]
0.82 [0.67 ; 0.99 ] CAPE-COVID, 2020, Jamaati, 2021, Metcovid, 2020, RECOVERY dexamethasone, 2020 4 0% 5,805 moderate not evaluable radiologic improvement (14-day)detailed results Jamaati, 2021 4.89 [1.15; 20.79]
4.89 [1.15 ; 20.79 ] Jamaati, 2021 1 0% 50 NA not evaluable viral clearance detailed results Tang X, 2020 1.78 [1.06; 3.00]
1.78 [1.06 ; 3.00 ] Tang X, 2020 1 0% 86 NA not evaluable viral clearance (time to event analysis only)detailed results Tang X, 2020 1.78 [1.06; 3.00]
1.78 [1.06 ; 3.00 ] Tang X, 2020 1 0% 86 NA not evaluable ICU admissiondetailed results GLUCOCOVID, 2020 0.85 [0.27; 2.67]
Tang X, 2020 1.00 [0.13; 7.45]
0.88 [0.33 ; 2.39 ] GLUCOCOVID, 2020, Tang X, 2020 2 0% 150 serious not evaluable serious adverse eventsdetailed results CODEX (Tomazini), 2020 0.53 [0.17; 1.62]
Edalatifard, 2020 0.81 [0.11; 6.17]
REMAP-CAP, fixed 7-day course, 2020 3.01 [0.33; 27.32]
REMAP-CAP, shock-dependent course, 2020 3.68 [0.42; 31.96]
1.06 [0.41 ; 2.77 ] CODEX (Tomazini), 2020, Edalatifard, 2020, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020 4 17% 841 serious not evaluable superinfectiondetailed results CAPE-COVID, 2020 0.81 [0.49; 1.34]
Metcovid, 2020 0.98 [0.65; 1.47]
0.91 [0.66 ; 1.25 ] CAPE-COVID, 2020, Metcovid, 2020 2 0% 542 moderate not evaluable 0.5 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-04-25 11:08 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 522,582,666,1149,1150,737,544,733
- roots T: 290
